Compare Crocs, Inc. (CROX) vs Tenet Healthcare Corporation (THC) Price & Performance

Crocs (CROX) trades at $114.98, down 0.19% on the day, with technical indicators showing a bearish trend despite recent earnings beats. The company reported strong Q2 2026 EPS of $4.55, beating expectations by $0.20, but faces challenges with a negative net income of -$81.20M for 2025. Valuation metrics remain attractive with a P/E of 10.37 and P/S of 1.48, while analyst consensus leans bullish with a $136.78 price target representing 19% upside potential.

CROX presents a mixed investment case with compelling valuation and strong brand positioning offset by recent profitability concerns. The key opportunity lies in the company's product innovation and HEYDUDE brand reset, while risks include consumer spending volatility and execution challenges. With 51% of analysts maintaining buy ratings, the stock offers potential upside if management can restore consistent profitability growth.

Tenet Healthcare (THC) trades at $263.78, up 1.52% today, with a bullish technical signal from moving averages and strong fundamental support. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 29, 2026. Revenue grew to $21.31B in 2025, with a robust net income margin of 9.9% and high return on equity of 53.31%, while valuation ratios like P/E of 10.07 and EV/EBITDA of 5.75 suggest potential undervaluation.

The outlook is positive, driven by earnings momentum and analyst consensus favoring buys, with a price target of $283.36 offering upside. Risks include reliance on surgical volumes and capital return sustainability, but strong cash flow and efficiency gains support growth. Investors should weigh solid fundamentals against sector-specific headwinds.